I contacted GW Pharmaceuticals as I couldn’t find any information that said CBD trials were finished and I got this email back:
…
"Thank you for your email enquiring about our schizophrenia research.
Please note that GWP42003 (cannabidiol [CBD]) is still in development and has not been approved by any medicinal regulatory authorities worldwide and is therefore not commercially available at this time.
GW Pharmaceuticals issued a press release in September 2015 detailing the findings of the most recent Phase 2 clinical trial exploring the use of CBD as a treatment for schizophrenia. All of the information currently available in the public domain relating to this research features on our website (www.gwpharm.com). GW is now analysing the data to fully understand the appropriate next steps regarding product development in schizophrenia. At this time it is difficult to indicate when further clinical trials may take place.
Further information about this completed study can be found here or by visiting www.clinicaltrials.gov and searching the ClinicalTrials.gov Identifier: NCT02006628.
My suggestion would be to occasionally monitor the GW website (address as above) for updates, as this is where we post the latest information.
Sorry that I cannot assist you any further on this occasion. Feel free to contact us again at www.medinfo@gwpharm.com should you have any further queries."
So not all hope is lost as yet.